SCHEMBL10123501

SCHEMBL10123501

N#C/N=C(/NC1CCCC1)N1CCN(S(=O)(=O)c2ccc(Cl)c(C(=O)Nc3nnc[nH]3)c2)CC1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.48
ALDH1A1 P00352 6/20 0.43
KDM4E B2RXH2 3/20 0.43
LMNA P02545 3/20 0.43
GFER P55789 1/20 0.43
TDP1 Q9NUW8 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
TSHR P16473 3/20 0.41
HTT P42858 2/20 0.41
HSD17B10 Q99714 1/20 0.41
MEN1 O00255 2/20 0.41
NPSR1 Q6W5P4 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
CNR2 P34972 1/20 0.40
POLB P06746 1/20 0.39
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL393916 0.89 KMT2A (0.49) KMT2AALDH1A1KDM4ELMNAGFER
SCHEMBL393917 0.89 KMT2A (0.49) KMT2AALDH1A1KDM4ELMNAGFER
SCHEMBL8312806 0.80 TDP1 (0.42) KMT2AALDH1A1LMNATDP1SMN1; SMN2
SCHEMBL12867415 0.76 KMT2A (0.49) KMT2AALDH1A1KDM4ELMNAGFER
SCHEMBL1170426 0.70 KMT2A (0.45) KMT2AALDH1A1KDM4ELMNAGFER
SCHEMBL1170425 0.70 KMT2A (0.45) KMT2AALDH1A1KDM4ELMNAGFER
SCHEMBL1169912 0.68 ALDH1A1 (0.51) KMT2AALDH1A1KDM4ELMNAGFER
SCHEMBL3596142 0.68 ALDH1A1 (0.54) KMT2AALDH1A1KDM4ELMNAGFER
SCHEMBL12674503 0.64 KMT2A (0.64) KMT2AALDH1A1KDM4ELMNAGFER
SCHEMBL397343 0.64 ALDH1A1 (0.51) KMT2AALDH1A1KDM4ELMNAGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120088779-A1 HETEROCYCLIC SULFONAMIDES CYTOKINETICS, INC. 2012-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088779-A1 HETEROCYCLIC SULFONAMIDES TNNI3, TNNT2, MYLK2 KMT2A 2395/4885ALDH1A1 4297/4885KDM4E 2012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.